Pharma stocks: Biocon up 3.84% on US FDA nod for Malaysia unit; Divi’s Lab gains 0.61%, Mankind Pharma slips 3.75%, GlaxoSmithKline drops 2.42%

At 10:13 AM, pharma stocks showed mixed trends, with Biocon emerging as the top gainer. The stock surged 3.84% to ₹374.80 after the company announced that its Malaysia insulin facility received clearance from the US FDA, boosting investor sentiment.

Divi’s Laboratories also edged up by 0.61%, trading at ₹5,806.40.

Advertisement

On the losing side, Mankind Pharma experienced a significant drop of 3.75% to ₹2,637.10, followed by GlaxoSmithKline Pharmaceuticals and Aurobindo Pharma, which declined by 2.42% and 2.08%, respectively.

Key Performers in the Pharma Sector:

  • Gainers:
    • Biocon: ₹374.80 (+3.84%)
    • Divi’s Lab: ₹5,806.40 (+0.61%)
  • Losers:
    • Mankind Pharma: ₹2,637.10 (-3.75%)
    • GlaxoSmithKline Pharmaceuticals: ₹2,137.50 (-2.42%)
    • Aurobindo Pharma: ₹1,174.60 (-2.08%)

Broader Pharma Sector Performance:

  • Torrent Pharma: ₹3,265.50 (-0.27%)
  • Glenmark: ₹1,533.95 (-0.50%)
  • Alkem Laboratories: ₹5,345.85 (-0.56%)
  • Lupin: ₹2,172.45 (-0.85%)
  • Sun Pharma: ₹1,765.45 (-1.08%)
  • Dr. Reddy’s Labs: ₹1,339.50 (-1.10%)
  • Cipla: ₹1,452.25 (-1.13%)

Biocon’s FDA clearance marks a significant milestone, reinforcing its commitment to global quality standards, while broader sector trends reflect a cautious market sentiment amid profit booking in key stocks.

Disclaimer: The information provided is for informational purposes only and should not be considered as financial advice. Please consult your financial advisor before making any investment decisions.